삼성서울병원

Ko En

Hematology-Oncology Kim, Ki Hyun M.D

Expertise
multiple myeloma, amyloidosis, bone marrow transplantation, CAR T-cell therapy
Treament Schedule 12 月
DATE
SUN
01
MON
02
TUE
03
WEB
04
THU
05
FRI
06
SAT
07
SUN
08
MON
09
TUE
10
WEB
11
THU
12
FRI
13
SAT
14
SUN
15
MON
16
TUE
17
WEB
18
THU
19
FRI
20
SAT
21
SUN
22
MON
23
TUE
24
WEB
25
THU
26
FRI
27
SAT
28
SUN
29
MON
30
TUE
31
AM
PM
Treament Schedule 01 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

2008 Ph.D. in Medicine Doctor of Philosophy, Graduate School, Chungbuk National University, Cheongju, Chungbuk, Korea
1991 Master of Science Master of Science, Graduate School, Seoul National University College of Medicine, Seoul, Korea

Post-Graduate Training

Fellowship   1999~2000 Samsung Medical Center
Residency   1995~1999 Samsung Medical Center
Internship   1991~1992 Seoul National University Hospital

Professional Appointments

2014~Present professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2014 Associate professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2009 Postdoc fellow Dana-Farber Cancer Institute
2002~2008 Assistant professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center

Professional Memberships

Member Korean Cancer Association
Member American Society of Hematology
Member The International Myeloma Working Group (IMWG)
Member International Myeloma Society
Member International society of amyloidosis (ISA)

Selected Publications

  • JACC CARDIOVASC IMAGING 2021 Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis Kim1, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • LANCET 2021 10.1016/S0140-6736(21)00592-4 Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Moreau1, P; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Risse, ML; Asset, G; Mace, S; Martin, T
    View PubMed
  • LEUKEMIA 2021 10.1038/s41375-021-01317-y A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri1, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17541 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach1, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed